Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 219-227

  Réti, Andrea ^a   Pap, Éva ^a   Adleff, Vilmos ^a   Jeney, András ^b   Kralovánszky, Judit ^a   Budai, Barna ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

5 fluorouracil; Cyclooxygenase 2; Dihydropyrimidine dehydrogenase; Indomethacin; NS 398

Indexed keywords

COLLAGEN TYPE 4; CYCLOOXYGENASE 2; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; INDOMETACIN; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; ANTINEOPLASTIC ANTIMETABOLITE; COLLAGEN; CYCLOOXYGENASE 2 INHIBITOR; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOENZYMATIC ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR VOLUME; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; ENZYMOLOGY; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIHYDROURACIL DEHYDROGENASE (NADP); DINOPROSTONE; DOWN-REGULATION; DRUG INTERACTIONS; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; HT29 CELLS; HUMANS; INDOMETHACIN; NITROBENZENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953049722     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1149-8     Document Type: Article

References (43)

1. Schnackerz KD, Dobritzsch D, Lindqvist Y, Cook PF (2004) Dihydropyrimidine dehydrogenase: a flavoprotein with four ironsulfur clusters. Biochim Biophys Acta 1701:61-74
2. Hoff PM (2000) The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (OR-ZEL™) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 18:331-342
3. Ahmed FY, Johnston SJ, Cassidy J et al (1999) Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 17:2439-2445
4. Kralovánszky J, Katona C, Jeney A et al (1999) 5-Ethyl-20-deoxyuridine,amodulator of both antitumour action and pharmacokinetics of 5-fluorouracil. J Cancer Res Clin Oncol 125:675-684
5. de Groot DJ, de Vries EG, Groen HJ, de Jong S (2007) Nonsteroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 61:52-69
6. Bennett A, Gaffen JD, Melhuish PB, Stamford IF (1987) Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate. Br J Pharmacol 91:229-235
7. Totzke G, Schulze-Osthoff K, Jänicke U (2003) Cyclooxygenase- 2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced appoptosis independently of COX-2 inhibition. Oncogene 22:8021-8030
8. Réti A, Barna G, Pap E, Adleff V, L Komlósi V, Jeney A, Kralovánszky J, Budai B (2008) Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low-dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells. Pathol Oncol Res. doi:10.1007/s12253-008- 9126-9
9. Réti A, Pap É, Zalatnai A, Jeney A, Kralovanszky J, Budai B (2009) Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts. Anticancer Res 29:3095-3102
10. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
11. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73:729-734
12. Eli Y, Przedecki F, Levin G, Kariv N, Raz A (2001) Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol 61:565-571
13. Matsuo Muneaki, Yoshida Nobuyuki, Zaitsu Masahumi, Ishii Kiyohisa, Hamasaki Yuhei (2004) Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089. J Neurooncol 66:285-292
14. Kern DH, Morgan CR, Hildebrand-Zanki SU (1988) In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloro-platinum(II). Cancer Res 48:117-121
15. Sweeney CJ (2003) Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol 26:S122-S125
16. Zaric J, Rüegg C (2005) Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem 280:1077-1085
17. Broom OJ, Massoumi R, Sjölander A (2006) Alpha2beta1 integrin signalling enhances cyclooxygenase-2 expression in intestinal epithelial cells. J Cell Physiol 209:950-958
18. Takahra T, Smart DE, Oakley F, Mann DA (2004) Induction of myofibroblast MMP-9 transcription in three-dimensional collagen I gel cultures: regulation by NF-kappaB, AP-1 and Sp1. Int J Biochem Cell Biol 36:353-363
19. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB (2006) The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta 1759:247-256
20. Abdelrahim M, Safe S (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68:317-329
21. Ogino M, Hanazono M (1999) Indomethacin preferentially augments 5-fluorouracil cytotoxicity in Colon 26 tumors by increasing the intracellular inflow of 5-fluorouracil. Int J Clin Oncol 4:22-25
22. Tachimori A, Yamada N, Amano R, Ohira M, Hirakawa K (2008) Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 28:629-638
23. Leonetti C, Scarsella M, Zupi G et al (2006) Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther 5:919-926
24. Ogino M, Minoura S (2001) Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int J Clin Oncol 6:84-89
25. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM (2005) Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11:1618-1628
26. Eichele K, Ramer R, Hinz B (2008) Decisive role of cyclooxygenase- 2 and lipocalin-type prostaglandin D synthase in chemotherapeutics- induced apoptosis of human cervical carcinoma cells. Oncogene 27:3032-3044
27. Shestopal SA, Johnson MR, Diasio RB (2000) Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta 1494:162-169
28. Mizutani Y, Kamoi K, Ukimura O, Kawauchi A, Miki T (2002) Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol 168:2650-2654
29. Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL (2007) Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 83:338-343
30. Adeyemo D, Imtiaz F, Toffa S, Lowdell M, Wickremasinghe RG, Winslet M (2001) Antioxidants enhance the susceptibility of colon carcinoma cells to 5-fluorouracil by augmenting the induction of the bax protein. Cancer Lett 164:77-84
31. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T (2002) Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 38:167-176
32. Dou J, Iwashita Y, Sasaki A, Kai S, Hirano S, Ohta M, Kitano S (2005) Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression. Liver Int 25: 148-152
33. Zhao L, Chen Z, Wang J et al (2009) Synergistic effect of 5-fluorouracil and flavonoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol. doi:10.1007/s00280-009-1053-2
34. Takechi T, Okabe H, Fujioka A,Murakami Y, FukushimaM(1998) Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn J Cancer Res 89:1144-1153
35. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278:175-184
36. Miyamoto S, Ochiai A, Boku N, Ohtsu A, Tahara M, Yoshida S, Okabe H, Takechi T, Fukushima M (2001) Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int J Oncol 18:705-713
37. Nishiyama M, Yamamoto W, Park JS et al (1999) Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5:2620-2628
38. Sakurai Y, Uraguchi T, Imazu H, Hasegawa S, Matsubara T, Ochiai M, Funabiki T (2004) Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU. Gastric Cancer 7:110-116
39. Sakurai Y, Yoshida I, Kamoshida S, Inaba K, Isogaki J, Komori Y, Uyama I, Tsutsumi Y (2008) Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 50-deoxy-5- fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res 28:1593-1602
40. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ (2004) Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-20-deoxyuridine. World J Gastroenterol 10:172-176
41. Kobunai T, Ooyama A, Sasaki S, Wierzba K, Takechi T, Fukushima M, Watanabe T, Nagawa H (2007) Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: data mining of the NCI-DTP data sets and validation with human tumour xenografts. Eur J Cancer 43:791-798
42. Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B (2007) Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer. Magy Onkol 51:113-125
43. Yamada H, Iinuma H, Watanabe T (2008) Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep 19:729-735